Center-Authored Papers

Filters: Author is Gray, Glenda E  [Clear All Filters]
2017
Corey L, Gray GE.  2017.  Preventing acquisition of HIV is the only path to an AIDS-free generation.. Proceedings of the National Academy of Sciences of the United States of America. 114(15):3798-3800.
2016
Leitman EM, Hurst J, Mori M, Kublin J, Ndung'u T, Walker BD, Carlson J, Gray GE, Matthews PC, Frahm N et al..  2016.  Lower Viral Loads and Slower CD4 Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.. The Journal of infectious diseases. Abstract
Gray GE, Laher F, Lazarus E, Ensoli B, Corey L.  2016.  Approaches to preventative and therapeutic HIV vaccines.. Current opinion in virology. 17:104-109. Abstract
Gray GE, Laher F, Doherty T, Karim SA, Hammer S, Mascola J, Beyrer C, Corey L.  2016.  Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS biology. 14(3):e1002372. Abstract
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N et al..  2016.  Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.. Clinical and vaccine immunology : CVI. 23(6):496-506. Abstract
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR et al..  2016.  Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.. PLoS pathogens. 12(7):e1005742. Abstract
2015
Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, de Bruyn G, Delany-Moretlwe S, Fife KH, Gray GE, Kapiga S et al..  2015.  Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K et al..  2015.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.. Journal of virology. 89(5):2507-19. Abstract
Moodie Z, Metch B, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C et al..  2015.  Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.. PloS one. 10(9):e0137666. Abstract
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC et al..  2015.  Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.. PloS one. 10(9):e0136626. Abstract
2014
Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker L-G.  2014.  The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.. International journal of STD & AIDS. 25(5):332-40. Abstract
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
2012
Latka MH, Fielding K, Gray GE, Bekker L-G, Nchabeleng M, Mlisana K, Nielson T, Roux S, Mkhize B, Mathebula M et al..  2012.  Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.. PloS one. 7(4):e31387. Abstract
2011
Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P et al..  2011.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.. Vaccine. 29(32):5203-9. Abstract
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
2010
Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E et al..  2010.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.. Lancet. 375(9717):824-33. Abstract
Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, Stevens WS, Donnell D, Campbell MS, Farquhar C et al..  2010.  Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk.. PloS one. 5(9):e12598. Abstract